In silico dosimetry of low-dose rate brachytherapy using radioactive nanoparticles

Seniwal, Baljeet; Freitas, Lucas Freitas de; Mendes, Bruno Melo; Lugão, Ademar B.; Katti, Kattesh V.; Fonseca, Telma Cristina Ferreira

doi:10.1088/1361-6560/abd671

Cited by 7 publications

(5 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one of our recent in silico dosimetry study ( 61 ), we replicated the cell survival curves for three preclinical studies ( 10 , 15 , 100 ), published in literature, on the use of radioactive nanocarriers as nanobrachytherapeutic agents using a mathematical model ( 101 ) and EGSnrc ( 102 ) MC code. The mathematical model used took into account the doubling rate of tumor cells, complete repair of sublethal damage, uptake rate, and washout rate of nanocarriers to and from tumor cell monoexponential function of time.…”

Section: Dosimetric Studies On Nanobrachytherapy Applications Using Monte Carlo Methodsmentioning

confidence: 99%

“…111 In also emits photons with energy greater than 200 keV and is not suitable for internal RT purposes or radiation dose enhancement through radiosensitization ( 13 ). In case of preclinical studies using xenograft models, the energy deposited to the tumor models is mainly due to these emitted Auger electrons and photoelectrons generated due to the interaction of low-energy photons and gold ( 7 , 61 ).…”

Section: Radionuclides For Nanobrachytherapymentioning

confidence: 99%

“…Further, the mode of radiosynthesis of nanoparticles and the length of the purification step (of radionuclides) must be selected according to the half-life of the radionuclide ( 54 , 55 ). In terms of the spatial penetration depth and energy of the emitted particles, Auger and β-emitting radionuclides are most suitable for the treatment of solid tumors such as brain, breast, and prostate tumors by using nanobrachytherapy procedures ( 5 , 13 , 61 ).…”

Section: Radionuclides For Nanobrachytherapymentioning

confidence: 99%

See 2 more Smart Citations

Recent Advances in Brachytherapy Using Radioactive Nanoparticles: An Alternative to Seed-Based Brachytherapy

et al. 2021

Self Cite

View full text Add to dashboard Cite

Interstitial brachytherapy (BT) is generally used for the treatment of well-confined solid tumors. One example of this is in the treatment of prostate tumors by permanent placement of radioactive seeds within the prostate gland, where low doses of radiation are delivered for several months. However, successful implementation of this technique is hampered due to several posttreatment adverse effects or symptoms and operational and logistical complications associated with it. Recently, with the advancements in nanotechnology, radioactive nanoparticles (radio-NPs) functionalized with tumor-specific biomolecules, injected intratumorally, have been reported as an alternative to seed-based BT. Successful treatment of solid tumors using radio-NPs has been reported in several preclinical studies, on both mice and canine models. In this article, we review the recent advancements in the synthesis and use of radio-NPs as a substitute to seed-based BT. Here, we discuss the limitations of current seed-based BT and advantages of radio-NPs for BT applications. Recent progress on the types of radio-NPs, their features, synthesis methods, and delivery techniques are discussed. The last part of the review focuses on the currently used dosimetry protocols and studies on the dosimetry of nanobrachytherapy applications using radio-NPs. The current challenges and future research directions on the role of radio-NPs in BT treatments are also discussed.

show abstract

Section: Dosimetric Studies On Nanobrachytherapy Applications Using Monte Carlo Methodsmentioning

confidence: 99%

Section: Radionuclides For Nanobrachytherapymentioning

confidence: 99%

Section: Radionuclides For Nanobrachytherapymentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Brachytherapy Using Radioactive Nanoparticles: An Alternative to Seed-Based Brachytherapy

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Modeling of the radiation absorbed doses in cancer cells in vitro or in tumours in vivo deposited by radiation nanomedicines provides insight into their potential effectiveness and informs on optimizing their design. Seniwal et al ( 2021 ) calculated cellular S-values using EGSnrc MC code and compared these to MIRDcell for spherical cells and spherical tumours with homogeneously distributed 198 Au, 103 Pd or 153 Sm. Based on the reported data for mangiferin (MCF)-functionalized 198 AuNP (Katti et al 2018 ), AuNP with a 103 Pd core (Laprise-Pelletier et al 2017 ) and cetuximab-conjugated carbon nanocapsules (NCs) incorporating 153 Sm (Wang et al 2020b ), they modeled the tumour uptake and washout of the NPs injected i.t., then applied a radiobiological model to predict the surviving fraction of tumour cells and the tumour volume post-treatment.…”

Section: Main Textmentioning

confidence: 99%

Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape

Reilly,

Georgiou,

Brown

et al. 2024

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Background Radiation nanomedicines are nanoparticles labeled with radionuclides that emit α- or β-particles or Auger electrons for cancer treatment. We describe here our 15 years scientific journey studying locally-administered radiation nanomedicines for cancer treatment. We further present a view of the radiation nanomedicine landscape by reviewing research reported by other groups. Main body Gold nanoparticles were studied initially for radiosensitization of breast cancer to X-radiation therapy. These nanoparticles were labeled with 111In to assess their biodistribution after intratumoural vs. intravenous injection. Intravenous injection was limited by high liver and spleen uptake and low tumour uptake, while intratumoural injection provided high tumour uptake but low normal tissue uptake. Further, [111In]In-labeled gold nanoparticles modified with trastuzumab and injected iintratumourally exhibited strong tumour growth inhibition in mice with subcutaneous HER2-positive human breast cancer xenografts. In subsequent studies, strong tumour growth inhibition in mice was achieved without normal tissue toxicity in mice with human breast cancer xenografts injected intratumourally with gold nanoparticles labeled with β-particle emitting 177Lu and modified with panitumumab or trastuzumab to specifically bind EGFR or HER2, respectively. A nanoparticle depot (nanodepot) was designed to incorporate and deliver radiolabeled gold nanoparticles to tumours using brachytherapy needle insertion techniques. Treatment of mice with s.c. 4T1 murine mammary carcinoma tumours with a nanodepot incorporating [90Y]Y-labeled gold nanoparticles inserted into one tumour arrested tumour growth and caused an abscopal growth-inhibitory effect on a distant second tumour. Convection-enhanced delivery of [177Lu]Lu-AuNPs to orthotopic human glioblastoma multiforme (GBM) tumours in mice arrested tumour growth without normal tissue toxicity. Other groups have explored radiation nanomedicines for cancer treatment in preclinical animal tumour xenograft models using gold nanoparticles, liposomes, block copolymer micelles, dendrimers, carbon nanotubes, cellulose nanocrystals or iron oxide nanoparticles. These nanoparticles were labeled with radionuclides emitting Auger electrons (111In, 99mTc, 125I, 103Pd, 193mPt, 195mPt), β-particles (177Lu, 186Re, 188Re, 90Y, 198Au, 131I) or α-particles (225Ac, 213Bi, 212Pb, 211At, 223Ra). These studies employed intravenous or intratumoural injection or convection enhanced delivery. Local administration of these radiation nanomedicines was most effective and minimized normal tissue toxicity. Conclusions Radiation nanomedicines have shown great promise for treating cancer in preclinical studies. Local intratumoural administration avoids sequestration by the liver and spleen and is most effective for treating tumours, while minimizing normal tissue toxicity.

show abstract

“…The overall pharmacokinetics of the nanoscale brachytherapy agents and their anatomical distribution are key points to calculating dosimetry. Although radiation dosimetry of nanoscale brachytherapy agents is essential for clinical translation, very few preclinical studies with dosimetry data have been reported to date. ,,, Overall, these preclinical dosimetry studies, using therapeutic radiolabeled NPs, could provide insight for basic treatment planning concerning the administration of therapeutic doses for future efficacious clinical studies.…”

Section: Dosimetry Of Nanoscale Brachytherapy Agentsmentioning

confidence: 99%

Cancer Brachytherapy at the Nanoscale: An Emerging Paradigm

Ghosh,

Lee,

Hsu

et al. 2023

Chemical & Biomedical Imaging

View full text Add to dashboard Cite

Brachytherapy is an established treatment modality that has been globally utilized for the therapy of malignant solid tumors. However, classic therapeutic sealed sources used in brachytherapy must be surgically implanted directly into the tumor site and removed after the requisite period of treatment. In order to avoid the trauma involved in the surgical procedures and prevent undesirable radioactive distribution at the cancerous site, welldispersed radiolabeled nanomaterials are now being explored for brachytherapy applications. This emerging field has been coined "nanoscale brachytherapy". Despite present-day advancements, an ongoing challenge is obtaining an advanced, functional nanomaterial that concurrently incorporates features of high radiolabeling yield, short labeling time, good radiolabeling stability, and long tumor retention time without leakage of radioactivity to the nontargeted organs. Further, attachment of suitable targeting ligands to the nanoplatforms would widen the nanoscale brachytherapy approach to tumors expressing various phenotypes. Molecular imaging using radiolabeled nanoplatforms enables noninvasive visualization of cellular functions and biological processes in vivo. In vivo imaging also aids in visualizing the localization and retention of the radiolabeled nanoplatforms at the tumor site for the requisite time period to render safe and effective therapy. Herein, we review the advancements over the last several years in the synthesis and use of functionalized radiolabeled nanoplatforms as a noninvasive substitute to standard brachytherapy sources. The limitations of present-day brachytherapy sealed sources are analyzed, while highlighting the advantages of using radiolabeled nanoparticles (NPs) for this purpose. The recent progress in the development of different radiolabeling methods, delivery techniques and nanoparticle internalization mechanisms are discussed. The preclinical studies performed to date are summarized with an emphasis on the current challenges toward the future translation of nanoscale brachytherapy in routine clinical practices.

show abstract

In silico dosimetry of low-dose rate brachytherapy using radioactive nanoparticles

Cited by 7 publications

References 45 publications

Recent Advances in Brachytherapy Using Radioactive Nanoparticles: An Alternative to Seed-Based Brachytherapy

Recent Advances in Brachytherapy Using Radioactive Nanoparticles: An Alternative to Seed-Based Brachytherapy

Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape

Cancer Brachytherapy at the Nanoscale: An Emerging Paradigm

Contact Info

Product

Resources

About